Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Share this content:
Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival
Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Pfizer announced results from the Phase 2 PALOMA-1 study that is investigating the use of palbociclib (PD-0332991) in combination with letrozole in patients with advanced breast cancer. Palbociclib is an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6 for the potential treatment of patients with breast cancer.

RELATED: Breast Cancer Resource Center

PALOMA-1 (also known as Study 1003 and TRIO-18) is designed to assess progression-free survival (PFS) in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer receiving palbociclib 125mg once daily (for three out of four weeks in repeated cycles) in combination with letrozole vs. letrozole alone (2.5mg once daily on a continuous regimen). Part 1 of the trial enrolled 66 patients with ER+, HER2- advanced breast cancer while Part 2 enrolled 99 additional patients whose tumors were selected for presence of biomarkers: cyclin D1 amplification and/or p16 loss.

PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with ER+, HER2- locally advanced or metastatic breast cancer. In women treated with palbociclib plus letrozole, the median PFS was 20.2 months, a statistically significant improvement compared to the 10.2 months of PFS in women who received letrozole alone (HR=0.488, 95% CI: 0.319, 0.748; P=0.0004). 

Palbociclib was granted Breakthrough Therapy designation from the FDA in April 2013, for the initial treatment of women with advanced or metastatic ER+, HER2- breast cancer. Two Phase 3 studies (PALOMA-2 and PALOMA-3) have been initiated to study palbociclib in advanced/metastatic breast cancer.

For more information call (800) 438-1985 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs